In the Best Interests of the Public Health... Janice Soreth, M.D. Acting Director Division of Anti-Infective Drug Products CDER/FDA.

Slides:

Advertisements

Similar presentations

NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS

Advertisements

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.

Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001.

Update on Therapies: Clinical Trials Timothy PM Whelan Assistant Professor of Medicine Medical Director, Interstitial Lung Disease Program University of.

Save Antibiotic Strength Health Plans Address the Challenge of Antibiotic Resistance Robert Scalettar, M.D. July 19, 2005.

Inaugural Conference April 28-30, 2005 Omni Hotel at CNN Center Atlanta, GA Robert Martin, DrPH, Director Division of Public Health Partnerships.

Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases: Workshop Toleration.

July 2015 PRABHAVATHI FERNANDES, PhD Founder, President and CEO How the PATH Act Can Rejuvenate Antibiotic R & D.

1 FDA Trial Design Requirements for CABP David M. Shlaes MD, PhD Anti-infectives Consulting, LLC Stonington, CT.

Recommended by the Sentinel Event Alert Advisory Group NATIONAL PATIENT SAFETY GOALS FY 2009.

Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.

Antibiotic Resistance: Incentives for Antimicrobial Development Mark J Goldberger MD MPH CDER/FDA.

Using AERS in Postmarketing Surveillance of Medication Errors Carol Holquist, RPh Director, Division of Medication Errors and Technical Support Office.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.

The Health Roundtable Meeting the Granny Test at a Microbiological Level Presenter: Counties Manukau Health Poster Session HRT1306 – Best Practice Health.

Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

Clinical Approach to the Diagnosis of SARS Joshua P. Metlay, MD, PhD VA Medical Center Division of General Internal Medicine Center for Clinical Epidemiology.

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.

PSA: Drugs, Antibiotics, & Pesticides Resistance By Haley Cole, Katelyn Le-Thompson, & Amanda Lucas.

Prudent Health Workshop Clinical Overview Dr Kurt Burkhardt (GP Partner/ Locality Clinical Director)

How Clinicians Use Data For Clinical Decision Making March 5, 2003 Anti-Infective Drug Advisory Committee How Clinicians Use Data For Clinical Decision.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

FDA Office of Orphan Products Development

MUSC Health Year in Review Great steps forward in 2014.

1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

1 Cardiovascular and Renal Drugs Advisory Committee Questions June 24, 2008 Ira Krefting, MD.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

1 Development of Antibacterial Drugs for Infections with Resistant Pathogens Antimicrobial Working Group of the Pharmaceutical Research and Manufacturers.

Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.

CCEB October 30 David J. Margolis MD PhD Associate Professor of Dermatology and Epidemiology Center for Clinical Epidemiology and Biostatistics University.

Single Competency Framework for Prescribers National Prescribing Centre (2012)

1 Antibiotic Resistance: An Update Janice Soreth, M.D. Director Division of Anti-Infective Drug Products February 20, 2002.

1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.

The Truth About Antibiotics From a Medical Perspective Amanda Anderson Clinic Worker.

Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 FDA’s Communication of Drug Safety Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research December 7-8, 2005 Welcome – Opening Remarks.

CDER / FDA1 Clinical Study Options for locally acting nasal suspension products Robert J. Meyer, MD Director, Div. Of Pulmonary and Allergy Drug Products.

U.S. Strategies to Improve Human Antibiotic Use Lauri A. Hicks, D.O. Director, Office of Antibiotic Stewardship April 13, 2016 National Center for Emerging.

An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.

Nosocomial Antibiotic Resistant Organisms

Antimicrobial Stewardship

Antibiotics: handle with care!

Patient Focused Drug Development An FDA Perspective

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS

YOUR ACTIONS PROTECT ANTIBIOTICS, RALLY TOGETHER AT

Professor Alan Johnson Department of HCAI & AMR

Antibiotic Stewardship in Pennsylvania

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Simone M. Shurland, Ph.D., Division of Anti-Infective Products

PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

The HCV Revolution: Are You and Your Practice Ready?

Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”

Antimicrobial Care Bundle

Registri sul tumore della prostata: esperienze internazionali

Anti-microbial resistance

Antibiotics: Handle with care!

Presentation transcript:

In the Best Interests of the Public Health... Janice Soreth, M.D. Acting Director Division of Anti-Infective Drug Products CDER/FDA

April 26, 2001 …On Resistance Encourage development of new drugs to treat patients infected with resistant bacteria Use antimicrobials prudently to preserve their usefulness

April 26, 2001 …On Safety Clinical trials are powered to address efficacy questions, not safety If safety concerns arise, there are three options: –Stop. –Do additional pre-marketing studies to define risk management. –Make post-marketing inquiry, with labeling to speak to careful use.

April 26, 2001 …On Safety/Lessons Learned Once prescribing patterns are established for a new drug, they are very difficult to change.

April 26, 2001 …In the Best Interest of the Public Health We need to do it right the first time

April 26, 2001 Dr Temple/JAMA “…the possibility of using more rigorous methods, namely, large simple trials, to detect such risks should be considered in some cases (e.g., where very wide exposure is expected).”

April 26, In the Best Interests of the Public Health “If a question is important, answering it may well be worth the cost and effort.”